Safety of enzalutamide in patients with mCRPC with hepatic dysfunction
10.3760/cma.j.cn112330-20210908-00014
- VernacularTitle:恩扎卢胺对肝功异常mCRPC患者的安全性
- Author:
Hong DU
1
;
Yu WANG
;
Yong LIAO
;
Mingxing QIU
;
Jun LI
Author Information
1. 电子科技大学附属医院 四川省人民医院泌尿外科，成都 610072
- Keywords:
Enzalutamide;
Prostate cancer;
Abiraterone acetate;
Adverse event
- From:
Chinese Journal of Urology
2021;42(Z2):47-50
- CountryChina
- Language:Chinese
-
Abstract:
In March 2019, a patient with advanced prostate cancer was diagnosed in Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, and the disease progressed to the stage of mCRPC after traditional endocrinotherapy. Serious adverse event occurred after 1 month of treatment with abiraterone, which result in drug withdrawal, and replaced therapy by enzalutamide, the effect was good.
